It adds to a growing body of evidence that glucagon-like peptide-1 (GLP-1) receptor agonists may have a place in tackling addiction to a variety of substances
However, its effectiveness in reducing body weight has led to its approval as a chronic weight management drug
Obesity SURMOUNT-1 Trial In adults with obesity (without diabetes): Tirzepatide (15 mg) : 20.9% average body weight reduction over 72 weeks Semaglutide (2.4 mg) (based on STEP trials): ~14.9% average reduction STEP 5 Long-Term Results Semaglutide also demonstrated durable effects: At 104 weeks, patients maintained ~15% weight loss on semaglutide 2.4 mg (STEP 5) SELECT Trial Cardiovascular Benefit Semaglutide significantly reduced major adverse cardiovascular events by 20% in people with obesity and pre-existing heart diseaseindicating benefit beyond weight loss
Jordy AB, Albayaty M, Breitschaft A, Anderson TW, Christiansen E, Houshmand-regaard A, Manigandan E, Bkdal TA
There is no emergency that justifies it
Lower circulating insulin levels allow your body's insulin receptors to become more responsive, breaking the cycle of resistance-driven weight gain